Zebrafish CML Inflammation Model for Cytokine Storm Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack an effective and economical way to screen anti-inflammatory agents for conditions like cytokine storm syndrome, which is associated with chronic inflammation and hyperinflammation, using animal models that are costly and complex to maintain.
Innovation Solution
A method using zebrafish embryos and adults is developed to induce acute cytokine storm and neuroparalysis by injecting CML, an advanced glycation end product, and assess the efficacy of test substances in alleviating these conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional animal models (mice, rats) are used to screen anti-inflammatory agents for cytokine storm syndrome, then the biological relevance and reliability of the model are improved, but the cost and complexity of maintaining the model increase
Solution Approach 1:
The patent uses zebrafish as a simplified copy of mammalian animal models. Zebrafish share conserved immune pathways and cytokine signaling mechanisms with mammals, allowing them to replicate cytokine storm syndrome characteristics while being easier to maintain. The transparent embryos and rapid development enable visual monitoring of inflammation and drug effects without complex infrastructure.
Solution Approach 2:
Zebrafish have a short lifespan (3-5 years) and rapid reproduction cycle, allowing quick generation of new model organisms. Their small size and low maintenance requirements compared to mice or rats reduce facility costs. The ability to produce large numbers of embryos enables parallel testing of multiple anti-inflammatory agents simultaneously.
2Reliability
If traditional animal models are used to screen anti-inflammatory agents, then the reliability of disease modeling is improved, but the time required for screening and the cost of maintenance increase
Solution Approach 1:
The patent segments the screening process into parallel tracks: embryo stage testing for developmental toxicity and immune response, and adult stage testing for functional inflammation models. This segmentation allows simultaneous evaluation of multiple agents at different developmental stages, reducing total screening time while maintaining comprehensive assessment.
Solution Approach 2:
Zebrafish embryos undergo rapid periodic development cycles, reaching relevant developmental stages within 24-48 hours. This periodic development enables quick progression through screening stages compared to mammalian models that require weeks or months to reach equivalent developmental points, significantly reducing screening time.
3Device complexity
If CML is used to induce inflammation in zebrafish, then the model simplicity and economic efficiency are improved, but the complexity of inducing and controlling the inflammatory response increases
Solution Approach 1:
The patent optimizes CML concentration and administration timing parameters to achieve consistent inflammatory responses. By controlling these parameters, the model maintains simplicity in setup while achieving reliable inflammation induction. The standardized protocol allows reproducible results across different experiments.
Data Source
AI summary
The present invention relates to zebrafish embryo and adult models constructed by inducing inflammation with carboxymethyllysine (CML), which causes glycation toxicity, and a method for screening anti-inflammatory agents using the same. The present invention provides a method for screening a novel anti-inflammatory agent using zebrafish in which embryonic death, acute cytokine storm, and neuro-paralysis has been induced, whereby inflammatory diseases can be prevented or treated in a more convenient and cost-effective manner.